The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

V.d

Pleural/pericardial effusion, ANA positive (DI lupus)

Publications

Mariette X, Gottenberg JE, Ravaud P, Combe B

Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries.

Rheumatology (Oxford, England). 2011;50(1):222-9

Wetter DA, Davis MD

Lupus-like syndrome attributable to anti-tumor necrosis factor alpha therapy in 14 patients during an 8-year period at Mayo Clinic.

Mayo Clinic proceedings. 2009;84(11):979-84

Porfyridis I, Kalomenidis I, Psallidas I, Stratakos G, Roussos C, Vassilakopoulos T, Stathopoulos GT

Etanercept-induced pleuropericardial lupus-like syndrome.

The European respiratory journal. 2009;33(4):939-41

Haake H, Köneke J, Amann K, vom Dahl J, Janssen U

[Development of systemic lupus erythematosus with focal proliferative lupus nephritis during anti-TNF-alpha therapy for psoriatic arthritis].

Medizinische Klinik (Munich, Germany : 1983). 2007;102(10):852-7